Rhythm Pharmaceuticals focuses on advancing care and precision medicines for patients and families dealing with hyperphagia and severe obesity resulting from rare melanocortin-4 receptor (MC4R) pathway diseases.

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

COM:RHYTHMTX

Rhythm Pharmaceuticals

Last Close

49.43

29/10 20:00

Market Cap

3.03B

Beta: -

Volume Today

178.24K

Avg: -

locale

market

industry

website

ipo date

peer of

competitor of

Metrics